Skip navigation

Strategies for Value Optimization in Real-World Data Generation and Analytics

September 27-28, 2017
  • Philadelphia, PA

Bart Barefoot
Director, VEO & Real World Evidence Policy & Advocacy,
Value Evidence and Outcomes (VEO), Global Medical
GlaxoSmithKline

Marc Berger
Chair, Real World Evidence Product Advisory Board
SHYFT

Kyle Brown
Founder & Former CEO
PatientCrossroads

Robert Boland
Associate Director, Emerging Science & Innovation
Johnson & Johnson

Anita Burrell
Founder & CEO
Anita Burrell Consulting LLC

Gregory Daniel, PhD, MPH
Deputy Director
Duke-Robert J. Margolis, MD, Center for Health Policy

Riad Dirani
Vice President, Global Health Economics and Outcomes Research
Teva

Michael Duong
Director, Medical Affairs, Evidence Generation
Hoffmann-La Roche

Janet Espirito, PharmD
Associate Director, Outcomes Research
McKesson Specialty Health

Richard Gliklich, MD
CEO
OM1

Tony Hebden
Vice President, Health Economics and Outcomes Research
AbbVie

Penny Levin, MS
Director, Global Regulatory Intelligence and Policy
Teva

Sachin Kamal-Bahl
Vice President and Head, Innovation Center, Patient and Health Impact
Pfizer Inc

David Miller, ScD SM
Head of RWE Methods, Analytics, Health Economics
UCB

Michael Pencina
Director, Biostatistics
Duke Clinical Research Institute

Stephanie Reisinger
President and GM Evalytica
Evidera

Deborah Sundal
SVP of Product Architecture, Enterprise Research and Development
UnitedHealth Group

Jeff Trotter
President
Continuum Clinical

Lisa Wruck, PhD
Director of Center of Predictive Medicine
Duke Clinical Research Institute

Bart Barefoot
Director, VEO & Real World Evidence Policy & Advocacy,
Value Evidence and Outcomes (VEO), Global Medical
GlaxoSmithKline

Marc Berger
Chair, Real World Evidence Product Advisory Board
SHYFT

Kyle Brown
Founder & Former CEO
PatientCrossroads

Robert Boland
Associate Director, Emerging Science & Innovation
Johnson & Johnson

Anita Burrell
Founder & CEO
Anita Burrell Consulting LLC

Gregory Daniel, PhD, MPH
Deputy Director
Duke-Robert J. Margolis, MD, Center for Health Policy

Riad Dirani
Vice President, Global Health Economics and Outcomes Research
Teva

Michael Duong
Director, Medical Affairs, Evidence Generation
Hoffmann-La Roche

Janet Espirito, PharmD
Associate Director, Outcomes Research
McKesson Specialty Health

Richard Gliklich, MD
CEO
OM1

Tony Hebden
Vice President, Health Economics and Outcomes Research
AbbVie

Penny Levin, MS
Director, Global Regulatory Intelligence and Policy
Teva

Sachin Kamal-Bahl
Vice President and Head, Innovation Center, Patient and Health Impact
Pfizer Inc

David Miller, ScD SM
Head of RWE Methods, Analytics, Health Economics
UCB

Michael Pencina
Director, Biostatistics
Duke Clinical Research Institute

Stephanie Reisinger
President and GM Evalytica
Evidera

Deborah Sundal
SVP of Product Architecture, Enterprise Research and Development
UnitedHealth Group

Jeff Trotter
President
Continuum Clinical

Lisa Wruck, PhD
Director of Center of Predictive Medicine
Duke Clinical Research Institute